pancreatitis
Conditions
Interventions
The bolus of Ringer'
s solution is administered at 5 ml/kg at the same time as the start of ERCP, and the Ringer'
s solution is administered at 3 ml/kg/h for 8 hours after ERCP.
Sponsors
Mie University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients over 20 years old 2) Patients who need ERCP 3) Patients who have never received treatment of papilla 4) Those who have obtained informed consent to participate in the research
Exclusion criteria
Exclusion criteria: 1) Patients with heart failure (NYHA II or more) 2) Patients with impaired renal function (eGFR<45mL/min/1.73m2) 3) Patients with respiratory failure (SpO2<90% in room air) 4) Patients with pancreatitis before ERCP 5) Patients with Performance Status >3 6) Patients with colostomy who cannot administer diclofenac sodium intra-rectally 7) Patients contraindicated with diclofenac sodium 8) Patients with postoperative reconstructed tract 9) Patients who cannot reach the papilla due to organic narrowing of the digestive tract 10) Patients who are pregnant or may be pregnant 11) Patients who are determined to be inappropriate for inclusion in the study by the co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the incidence of post-ERCP pancreatitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include PEP severity, and hydration-related complications. | — |
Countries
Japan
Contacts
Public ContactReiko Yamada
Mie University Hospital Gastroenterology and Hepatology
Outcome results
None listed